These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21546641)

  • 1. Stability of compounded thioguanine oral suspensions.
    Aliabadi HM; Romanick M; Somayaji V; Mahdipoor P; Lavasanifar A
    Am J Health Syst Pharm; 2011 May; 68(10):900-8. PubMed ID: 21546641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of buffer and antioxidant on stability of a mercaptopurine suspension.
    Aliabadi HM; Romanick M; Desai S; Lavasanifar A
    Am J Health Syst Pharm; 2008 Mar; 65(5):441-7. PubMed ID: 18281736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability and Beyond-Use Date of a Compounded Thioguanine Suspension.
    Gilda SS; Kolling WM; Nieto M; McPherson T
    J Pharm Technol; 2021 Feb; 37(1):23-29. PubMed ID: 34752544
    [No Abstract]   [Full Text] [Related]  

  • 4. Stability of extemporaneously prepared cinacalcet oral suspensions.
    Thomson K; Hutchinson DJ; Chablani L
    Am J Health Syst Pharm; 2018 May; 75(9):e236-e240. PubMed ID: 29691267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of acetazolamide in suspension compounded from tablets.
    Alexander KS; Haribhakti RP; Parker GA
    Am J Hosp Pharm; 1991 Jun; 48(6):1241-4. PubMed ID: 1858804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of zonisamide in extemporaneously compounded oral suspensions.
    Abobo CV; Wei B; Liang D
    Am J Health Syst Pharm; 2009 Jun; 66(12):1105-9. PubMed ID: 19498126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date.
    Peacock GF; Sauvageot J; Hill A; Killian A
    Int J Pharm Compd; 2016; 20(1):81-5. PubMed ID: 27125058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding.
    Zhao F; Dave VS; Mar MZ; Perri JR
    Int J Pharm Compd; 2018; 22(5):433-439. PubMed ID: 30384342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions.
    Caruthers RL; Johnson CE
    Am J Health Syst Pharm; 2007 Jul; 64(14):1513-5. PubMed ID: 17617502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of sotalol hydrochloride in extemporaneously prepared oral suspension formulations.
    Sidhom MB; Rivera N; Almoazen H; Taft DR; Kirschenbaum HL
    Int J Pharm Compd; 2005; 9(5):402-6. PubMed ID: 23925139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4.
    Polonini H; da Silva SL; Cunha CN; Ferreira AO; Anagnostou K; Dijkers E
    Int J Pharm Compd; 2020; 24(3):252-262. PubMed ID: 32401746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of extemporaneously prepared moxifloxacin oral suspensions.
    Hutchinson DJ; Johnson CE; Klein KC
    Am J Health Syst Pharm; 2009 Apr; 66(7):665-7. PubMed ID: 19299374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of extemporaneously prepared rufinamide oral suspensions.
    Hutchinson DJ; Liou Y; Best R; Zhao F
    Ann Pharmacother; 2010 Mar; 44(3):462-5. PubMed ID: 20150505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions.
    Svirskis D; Lin SW; Brown H; Sangaroomthong A; Shin D; Wang Z; Xu H; Dean R; Vareed P; Jensen M; Wu Z
    Int J Pharm Compd; 2018; 22(2):164-171. PubMed ID: 29877863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of extemporaneously prepared glycopyrrolate oral suspensions.
    Cober MP; Johnson CE; Sudekum D; Penprase K
    Am J Health Syst Pharm; 2011 May; 68(9):843-5. PubMed ID: 21515869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children.
    Pramann LA; Davidow LW; van Haandel L; Funk RS
    Int J Pharm Compd; 2016; 20(3):257-261. PubMed ID: 28333668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of allopurinol and of five antineoplastics in suspension.
    Dressman JB; Poust RI
    Am J Hosp Pharm; 1983 Apr; 40(4):616-8. PubMed ID: 6846371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The stability of quetiapine oral suspension compounded from commercially available tablets.
    Tran J; Gervase MA; Evans J; Deville R; Dong X
    PLoS One; 2021; 16(8):e0255963. PubMed ID: 34375349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of an extemporaneously compounded minoxidil oral suspension.
    Song Y; Chin ZW; Ellis D; Lwin EMP; Turner S; Williams D; Garg S
    Am J Health Syst Pharm; 2018 Mar; 75(5):309-315. PubMed ID: 29472513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of extemporaneously prepared rifaximin oral suspensions.
    Cober MP; Johnson CE; Lee J; Currie K
    Am J Health Syst Pharm; 2010 Feb; 67(4):287-9. PubMed ID: 20133533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.